Cargando…

Higher tacrolimus trough levels and time in the therapeutic range are associated with the risk of acute rejection in the first month after renal transplantation

BACKGROUND: Tacrolimus trough levels (C(0)) are used in most transplant centres for therapeutic drug monitoring (TDM) of tacrolimus (Tac). The target range of Tac C(0) has been remarkably changed, with a target as low as 3–7 ng/ml in the 2009 European consensus conference and a target of 4–12 ng/ml...

Descripción completa

Detalles Bibliográficos
Autores principales: Nguyen, Thi Van Anh, Nguyen, Huu Duy, Nguyen, Thi Lien Huong, Le, Viet Thang, Nguyen, Xuan Kien, Tran, Viet Tien, Le, Dinh Tuan, Ta, Ba Thang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10169362/
https://www.ncbi.nlm.nih.gov/pubmed/37158838
http://dx.doi.org/10.1186/s12882-023-03188-0
_version_ 1785039037927522304
author Nguyen, Thi Van Anh
Nguyen, Huu Duy
Nguyen, Thi Lien Huong
Le, Viet Thang
Nguyen, Xuan Kien
Tran, Viet Tien
Le, Dinh Tuan
Ta, Ba Thang
author_facet Nguyen, Thi Van Anh
Nguyen, Huu Duy
Nguyen, Thi Lien Huong
Le, Viet Thang
Nguyen, Xuan Kien
Tran, Viet Tien
Le, Dinh Tuan
Ta, Ba Thang
author_sort Nguyen, Thi Van Anh
collection PubMed
description BACKGROUND: Tacrolimus trough levels (C(0)) are used in most transplant centres for therapeutic drug monitoring (TDM) of tacrolimus (Tac). The target range of Tac C(0) has been remarkably changed, with a target as low as 3–7 ng/ml in the 2009 European consensus conference and a target of 4–12 ng/ml (preferably to 7–12 ng/ml) following the second consensus report in 2019. Our aim was to investigate whether reaching early Tac therapeutic targets and maintaining time in the therapeutic range (TTR) according to the new recommendations may be necessary for preventing acute rejection (AR) during the first month after transplantation. METHODS: A retrospective study including 160 adult renal transplant patients (113 men and 47 women) with a median age of 36.3 (20–44) years was conducted between January 2018 and December 2019 at 103 Military Hospital (Vietnam). Tac trough levels were recorded in the first month, and episodes of AR were confirmed by kidney biopsy. Tac TTR was calculated as the percentage of time within the target range of 7–12 ng/ml, according to the 2019 second consensus report. Multivariate Cox analysis was performed to identify the correlation between the Tac target range and TTR with AR. RESULTS: In the first month after RT, 14 (8.8%) patients experienced AR. There was a significant difference in the incidence of AR between the Tac level groups of < 4, 4–7 and > 7 ng/ml (p = 0.0096). In the multivariate Cox analysis, after adjusting for related factors, a mean Tac level > 7 ng/ml was associated with an 86% decreased risk of AR compared with that of 4–7 ng/ml in the first month (HR, 0.14; 95% CI, 0.03–0.66; p = 0.0131). Every 10% increase in TTR was associated with a 28% lower risk of AR (HR, 0.72; 95% CI, 0.55–0.94; p = 0.014). CONCLUSION: Gaining and maintaining Tac C(0) according to the 2019 second consensus report might reduce the risk of AR in the first month following transplantation. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12882-023-03188-0.
format Online
Article
Text
id pubmed-10169362
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-101693622023-05-11 Higher tacrolimus trough levels and time in the therapeutic range are associated with the risk of acute rejection in the first month after renal transplantation Nguyen, Thi Van Anh Nguyen, Huu Duy Nguyen, Thi Lien Huong Le, Viet Thang Nguyen, Xuan Kien Tran, Viet Tien Le, Dinh Tuan Ta, Ba Thang BMC Nephrol Research BACKGROUND: Tacrolimus trough levels (C(0)) are used in most transplant centres for therapeutic drug monitoring (TDM) of tacrolimus (Tac). The target range of Tac C(0) has been remarkably changed, with a target as low as 3–7 ng/ml in the 2009 European consensus conference and a target of 4–12 ng/ml (preferably to 7–12 ng/ml) following the second consensus report in 2019. Our aim was to investigate whether reaching early Tac therapeutic targets and maintaining time in the therapeutic range (TTR) according to the new recommendations may be necessary for preventing acute rejection (AR) during the first month after transplantation. METHODS: A retrospective study including 160 adult renal transplant patients (113 men and 47 women) with a median age of 36.3 (20–44) years was conducted between January 2018 and December 2019 at 103 Military Hospital (Vietnam). Tac trough levels were recorded in the first month, and episodes of AR were confirmed by kidney biopsy. Tac TTR was calculated as the percentage of time within the target range of 7–12 ng/ml, according to the 2019 second consensus report. Multivariate Cox analysis was performed to identify the correlation between the Tac target range and TTR with AR. RESULTS: In the first month after RT, 14 (8.8%) patients experienced AR. There was a significant difference in the incidence of AR between the Tac level groups of < 4, 4–7 and > 7 ng/ml (p = 0.0096). In the multivariate Cox analysis, after adjusting for related factors, a mean Tac level > 7 ng/ml was associated with an 86% decreased risk of AR compared with that of 4–7 ng/ml in the first month (HR, 0.14; 95% CI, 0.03–0.66; p = 0.0131). Every 10% increase in TTR was associated with a 28% lower risk of AR (HR, 0.72; 95% CI, 0.55–0.94; p = 0.014). CONCLUSION: Gaining and maintaining Tac C(0) according to the 2019 second consensus report might reduce the risk of AR in the first month following transplantation. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12882-023-03188-0. BioMed Central 2023-05-08 /pmc/articles/PMC10169362/ /pubmed/37158838 http://dx.doi.org/10.1186/s12882-023-03188-0 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Nguyen, Thi Van Anh
Nguyen, Huu Duy
Nguyen, Thi Lien Huong
Le, Viet Thang
Nguyen, Xuan Kien
Tran, Viet Tien
Le, Dinh Tuan
Ta, Ba Thang
Higher tacrolimus trough levels and time in the therapeutic range are associated with the risk of acute rejection in the first month after renal transplantation
title Higher tacrolimus trough levels and time in the therapeutic range are associated with the risk of acute rejection in the first month after renal transplantation
title_full Higher tacrolimus trough levels and time in the therapeutic range are associated with the risk of acute rejection in the first month after renal transplantation
title_fullStr Higher tacrolimus trough levels and time in the therapeutic range are associated with the risk of acute rejection in the first month after renal transplantation
title_full_unstemmed Higher tacrolimus trough levels and time in the therapeutic range are associated with the risk of acute rejection in the first month after renal transplantation
title_short Higher tacrolimus trough levels and time in the therapeutic range are associated with the risk of acute rejection in the first month after renal transplantation
title_sort higher tacrolimus trough levels and time in the therapeutic range are associated with the risk of acute rejection in the first month after renal transplantation
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10169362/
https://www.ncbi.nlm.nih.gov/pubmed/37158838
http://dx.doi.org/10.1186/s12882-023-03188-0
work_keys_str_mv AT nguyenthivananh highertacrolimustroughlevelsandtimeinthetherapeuticrangeareassociatedwiththeriskofacuterejectioninthefirstmonthafterrenaltransplantation
AT nguyenhuuduy highertacrolimustroughlevelsandtimeinthetherapeuticrangeareassociatedwiththeriskofacuterejectioninthefirstmonthafterrenaltransplantation
AT nguyenthilienhuong highertacrolimustroughlevelsandtimeinthetherapeuticrangeareassociatedwiththeriskofacuterejectioninthefirstmonthafterrenaltransplantation
AT levietthang highertacrolimustroughlevelsandtimeinthetherapeuticrangeareassociatedwiththeriskofacuterejectioninthefirstmonthafterrenaltransplantation
AT nguyenxuankien highertacrolimustroughlevelsandtimeinthetherapeuticrangeareassociatedwiththeriskofacuterejectioninthefirstmonthafterrenaltransplantation
AT tranviettien highertacrolimustroughlevelsandtimeinthetherapeuticrangeareassociatedwiththeriskofacuterejectioninthefirstmonthafterrenaltransplantation
AT ledinhtuan highertacrolimustroughlevelsandtimeinthetherapeuticrangeareassociatedwiththeriskofacuterejectioninthefirstmonthafterrenaltransplantation
AT tabathang highertacrolimustroughlevelsandtimeinthetherapeuticrangeareassociatedwiththeriskofacuterejectioninthefirstmonthafterrenaltransplantation